Literature DB >> 15694927

Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP.

Jose A Aguirre1, Jan Kehr, Takashi Yoshitake, Fang-Ling Liu, Alicia Rivera, Sergio Fernandez-Espinola, Beth Andbjer, Giuseppina Leo, Andrew D Medhurst, Luigi F Agnati, Kjell Fuxe.   

Abstract

The mGluR5 antagonist MPEP was used to study the role of mGluR5 in MPTP-induced injury of the nigrostriatal DA neurons. The findings indicate that acute blockade of mGluR5 may result in neuroprotective actions against MPTP neurotoxicity on nigral DA cell bodies and striatal DA terminals using stereological analysis of TH immunoreactivity and microdensitometry. Biochemical analysis showed no restoration of DA levels and metabolism indicating a maintained reduction of DA transmission.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15694927     DOI： 10.1016/j.brainres.2004.11.040

Source DB:  PubMed          Journal:  Brain Res        ISSN： 0006-8993            Impact factor:   3.252


  18 in total

1.  In vivo positron emission tomography imaging with [¹¹C]ABP688: binding variability and specificity for the metabotropic glutamate receptor subtype 5 in baboons.

Authors:  Christine DeLorenzo; Matthew S Milak; Kathleen G Brennan; J S Dileep Kumar; J John Mann; Ramin V Parsey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-29       Impact factor: 9.236

2.  On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson's disease: studies with the P2X(7) receptor antagonist A-438079.

Authors:  Daniel Marcellino; Diana Suárez-Boomgaard; María Dolores Sánchez-Reina; José A Aguirre; Takashi Yoshitake; Shimako Yoshitake; Beth Hagman; Jan Kehr; Luigi F Agnati; Kjell Fuxe; Alicia Rivera
Journal:  J Neural Transm (Vienna)       Date:  2010-04-13       Impact factor: 3.575

Review 3.  Intramembrane receptor-receptor interactions: a novel principle in molecular medicine.

Authors:  K Fuxe; M Canals; M Torvinen; D Marcellino; A Terasmaa; S Genedani; G Leo; D Guidolin; Z Diaz-Cabiale; A Rivera; L Lundstrom; U Langel; J Narvaez; S Tanganelli; C Lluis; S Ferré; A Woods; R Franco; L F Agnati
Journal:  J Neural Transm (Vienna)       Date:  2006-10-27       Impact factor: 3.575

4.  In vivo variation in metabotropic glutamate receptor subtype 5 binding using positron emission tomography and [11C]ABP688.

Authors:  Christine DeLorenzo; J S Dileep Kumar; J John Mann; Ramin V Parsey
Journal:  J Cereb Blood Flow Metab       Date:  2011-07-27       Impact factor: 6.200

5.  Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.

Authors:  Gunasingh J Masilamoni; James W Bogenpohl; David Alagille; Kristen Delevich; Gilles Tamagnan; John R Votaw; Thomas Wichmann; Yoland Smith
Journal:  Brain       Date:  2011-07       Impact factor: 13.501

6.  URB597 and the Cannabinoid WIN55,212-2 Reduce Behavioral and Neurochemical Deficits Induced by MPTP in Mice: Possible Role of Redox Modulation and NMDA Receptors.

Authors:  Angel Escamilla-Ramírez; Esperanza García; Guadalupe Palencia-Hernández; Ana Laura Colín-González; Sonia Galván-Arzate; Isaac Túnez; Julio Sotelo; Abel Santamaría
Journal:  Neurotox Res       Date:  2017-01-14       Impact factor: 3.911

Review 7.  Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

Authors:  Clare Finlay; Susan Duty
Journal:  J Neural Transm (Vienna)       Date:  2014-02-21       Impact factor: 3.575

8.  Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity.

Authors:  Diana L Price; Edward Rockenstein; Kiren Ubhi; Van Phung; Natalie MacLean-Lewis; David Askay; Anna Cartier; Brian Spencer; Christina Patrick; Paula Desplats; Mark H Ellisman; Eliezer Masliah
Journal:  PLoS One       Date:  2010-11-16       Impact factor: 3.240

Review 9.  Glutamate receptors as therapeutic targets for Parkinson's disease.

Authors:  Kari A Johnson; P Jeffrey Conn; Colleen M Niswender
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

10.  Activation of mGlu3 receptors stimulates the production of GDNF in striatal neurons.

Authors:  Giuseppe Battaglia; Gemma Molinaro; Barbara Riozzi; Marianna Storto; Carla L Busceti; Paola Spinsanti; Domenico Bucci; Valentina Di Liberto; Giuseppina Mudò; Corrado Corti; Mauro Corsi; Ferdinando Nicoletti; Natale Belluardo; Valeria Bruno
Journal:  PLoS One       Date:  2009-08-12       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.